New eye injection could mean fewer doctor visits for wet AMD patients
NCT ID NCT07557121
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called AIV007 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. About 35 participants will receive either AIV007 or the standard treatment Eylea. The goal is to see if AIV007 can improve vision and reduce the need for frequent injections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could eye drops replace injections for a leading cause of blindness?
- Could a daily eye gel replace injections for wet AMD?
- New eye injection could reduce treatment frequency for wet AMD
- New study aims to keep macular disease patients on track with eye injections
- New syringe for eye disease injections passes usability test
- New eye drug OLN324 tested for wet AMD and diabetic swelling